BofA analyst Jason Gerberry raised the firm’s price target on Eli Lilly (LLY) to $1,294 from $1,293 and keeps a Buy rating on the shares. Following Foundayo’s U.S. approval for weight loss, which came slightly ahead of the firm’s assumption, BofA fine tuned near-term estimates reflecting launch pricing and anticipated early dose-mix.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Foundayo approval puts Lilly on equal footing with Novo, says Morgan Stanley
- CEO says Lilly against push to pass drug pricing deals into law, CNBC reports
- Eli Lilly Stock (LLY) Surges as FDA Approves Weight-Loss Pill
- Eli Lilly shares should react positively to Foundayo approval, says BMO Capital
- Novo Nordisk in focus as FDA approves Eli Lilly’s Foundayo